Clinical Status 2006 -
Avantogen Oncology Inc. (AVTO), Los Angeles, Calif.
Bioaccelerate Holdings Inc. (BACL), New York, N.Y.
RESprotect GmbH, Dresden, Germany
-
Product: RP101
- Business: Cancer
- Molecular target: STAT3 mRNA; Apex gene
- Description: Inhibits induced chemoresistance and enhances chemosensitivity
- Indication: Treat advanced pancreatic cancer
- Endpoint: NA
- Status: Interim Phase I data
- Milestone: Submit IND (4Q06); start Phase II (early 2007)
- Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39% at 6 and 12 months, respectively. The estimated median survival was 9.3 months.
-
Product: RP101
- Business: Cancer
- Molecular target: STAT3 mRNA; Apex gene
- Description: Inhibits induced chemoresistance and enhances chemosensitivity
- Indication: Treat advanced pancreatic cancer
- Endpoint: NA
- Status: Phase II start
- Milestone: Start Phase II (early 2007)
- By early next year, AVTO will begin a Phase II trial comparing 750 mg daily of RP101 plus gemcitabine to gemcitabine plus placebo.
|
